IQVIA Holdings Inc. (IQV) SEC Filings & Earnings Calls
EquiReason read 18 IQVIA Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 46.0B
- P/E TTM
- 34.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
23 Sep 20268-K · 1.01, 2.03IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings.open
Risks flagged
Higher interest expense from 6.375% coupon vs. 5.000% on redeemed notes increases annual interest cost.
“6.375% senior notes due 2034 issued to redeem 5.000% notes due 2026.”
9 Sep 20268-K · 8.01IQVIA subsidiary intends to raise $2B via senior notes due 2034 at 6.375% to refinance existing debt and revolver; pricing and purchase agreement executed.open
Risks flagged
Increased leverage from new debt issuance, though used for refinancing.
“$2B new senior notes at 6.375% interest rate.”
28 Jul 202610-QIQVIA reported Q2 2026 revenue of $4,368M (+8.7% YoY) with stable margins and increased restructuring costs.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $4.37B | +9% y/y |
| Revenue · H1-2026 | $8.52B | +9% y/y |
| Commercial Solutions Revenue · Commercial Solutions · Q2-2026 | $1.79B | +9% y/y |
| R&D Solutions Revenue · Research & Development Solutions · Q2-2026 | $2.58B | +9% y/y |
| Backlog · Research & Development Solutions · Q2-2026 | $34.20B | |
| Operating Cash Flow · H1-2026 | $1.18B | +16% y/y |
| Employees · Q2-2026 | 94,000 |
Risks flagged
Restructuring execution risk
“Restructuring costs increased to $63M in Q2 2026 from $32M in Q2 2025, with actions expected through 2027.”
High debt levels
“Total indebtedness of $16,081 million as of June 30, 2026.”
Interest expense increase
“Interest expense increased to $197M in Q2 2026 from $182M in Q2 2025 due to higher outstanding debt balances.”
28 Jul 20268-K · 2.02Revenue $4.37B (+9% y/y); Adjusted EBITDA $994M (+9% y/y); Adjusted Diluted Earnings per Share $3.15 (+12% y/y); Guidance: Revenue guidance raised to $17,275M-$17,475M (mid-point 6.5% growth vs prior 5.8%); Adjusted EBITDA to $4,000M-$4,050earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $4.37B | +9% y/y |
| Adjusted EBITDA · Q2-2026 | $994M | +9% y/y |
| Adjusted Diluted Earnings per Share · Q2-2026 | $3.15 | +12% y/y |
| R&D Solutions Net New Bookings · Research & Development Solutions · Q2-2026 | $3.15B | +19% y/y |
| R&D Solutions Contracted Backlog · Research & Development Solutions · Q2-2026 | $34.20B | |
| Operating Cash Flow · Q2-2026 | $558M | +26% y/y |
| Free Cash Flow · Q2-2026 | $360M | +23% y/y |
Guidance
Revenue guidance raised to $17,275M-$17,475M (mid-point 6.5% growth vs prior 5.8%); Adjusted EBITDA to $4,000M-$4,050M; Adjusted EPS to $12.80-$13.00
IQVIA raised full-year 2026 guidance across all key metrics, citing stronger organic revenue growth, record bookings, and favorable forward-looking indicators.
Risks flagged
Foreign exchange headwinds partially offset guidance raise; M&A integration risks remain.
“Guidance assumes ~20 bps FX tailwind vs prior 100 bps; M&A contribution assumed 200 bps vs prior 150 bps.”
11 Jun 20268-K · 1.01, 2.03IQVIA Inc. issued €950M of 4.625% senior notes due 2033 to refinance existing indebtedness. Unsecured, semi-annual interest, callable with make-whole premium. Net proceeds used for debt refinancing and fees.open
Risks flagged
Refinancing risk managed; interest rate fixed at 4.625%.
“Notes bear interest at 4.625% per year, maturing 2033.”
4 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Interest rate risk locked at 4.625%.
“Notes bear interest at 4.625% per annum.”
3 Jun 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Potential refinancing risk if offering fails.
“Subject to market conditions.”
7 May 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement); filed financial statements and exhibits with this reportopen
Risks flagged
Buyback may reduce financial flexibility.
“The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time.”
5 May 20268-K · 2.02Revenue $4.15B (+8% y/y); GAAP Net Income $274M; Adjusted EBITDA $932M (+6% y/y); Guidance: FY2026 Adj. Diluted EPS raised to $12.65-$12.95; revenue reaffirmed $17.15B-$17.35B; Adj. EBITDA reaffirmed $3.975B-$4.025Bearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $4.15B | +8% y/y |
| GAAP Net Income · Q1-2026 | $274M | |
| Adjusted EBITDA · Q1-2026 | $932M | +6% y/y |
| GAAP Diluted Earnings per Share · Q1-2026 | $1.61 | |
| Adjusted Diluted Earnings per Share · Q1-2026 | $2.90 | +7% y/y |
| Commercial Solutions Revenue · Commercial Solutions · Q1-2026 | $1.75B | +12% y/y |
| R&D Solutions Revenue · R&D Solutions · Q1-2026 | $2.40B | +6% y/y |
| R&D Solutions Contracted Backlog · R&D Solutions · Q1-2026 | $34.20B | |
| R&D Solutions Net New Bookings · R&D Solutions · Q1-2026 | $2.50B | |
| Operating Cash Flow · Q1-2026 | $618M | +9% y/y |
Guidance
FY2026 Adj. Diluted EPS raised to $12.65-$12.95; revenue reaffirmed $17.15B-$17.35B; Adj. EBITDA reaffirmed $3.975B-$4.025B
Raised Adj. EPS guidance on strong Q1 beat; reaffirmed revenue and EBITDA; strong backlog and bookings support outlook.
Risks flagged
High leverage
“Net debt $13.9B; net leverage ratio 3.62x trailing twelve-month Adjusted EBITDA.”
Foreign exchange exposure
“Guidance assumes ~100 bps FX tailwind; constant currency growth lower than reported.”
5 May 202610-QRevenue $4.15B (+8% y/y); Net Income $514M (+4% y/y); Operating Cash Flow $618M (+9% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $4.15B | +8% y/y |
| Net Income · Q1-2026 | $514M | +4% y/y |
| Operating Cash Flow · Q1-2026 | $618M | +9% y/y |
| Commercial Solutions Revenue · Commercial Solutions · Q1-2026 | $1.75B | +12% y/y |
| R&D Solutions Revenue · Research & Development Solutions · Q1-2026 | $2.40B | +6% y/y |
| R&D Solutions Backlog · Research & Development Solutions · Q1-2026 | $34.20B | |
| Employees · Q1-2026 | 93,000 |
Risks flagged
Restructuring execution risk
“Restructuring costs incurred during 2026 and 2025 were due to ongoing efforts to streamline our global operations and reduce overcapacity to adapt to changing market conditions and integrate acquisitions.” · word for word
Foreign exchange exposure
“In the first three months of 2026, approximately 30% of our revenues were denominated in currencies other than the United States dollar.” · word for word
High leverage
“As of March 31, 2026, we had $15,908 million of total indebtedness.” · word for word
23 Apr 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersopen
Risks flagged
Potential dilution from new equity plan.
“2026 Plan authorizes a range of performance- and time-based equity-based awards.”
27 Feb 2026DEF 14AIQVIA filed its 2026 proxy statement (DEF 14A) detailing executive compensation, governance, and shareholder proposals.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $16.30B | +6% y/y |
| Adjusted EBITDA · FY2025 | $3.80B | +3% y/y |
| Adjusted Diluted EPS · FY2025 | $11.92 | +7% y/y |
| Free Cash Flow · FY2025 | $2.10B | |
| Backlog · R&DS · FY2025 | $32.70B | +5% y/y |
| Next Twelve Months Revenue from Backlog · R&DS · FY2025 | $8.30B | +5% y/y |
| Net New Business (R&DS) · R&DS · FY2025 | $10.00B | |
| Net New Customers (R&DS) · R&DS · FY2025 | 400 | |
| Employees · FY2025 | 93,000 | |
| Voluntary Attrition Rate · FY2025 | 10.5% |
Risks flagged
Industry headwinds and policy changes
“Through the first half of 2025, IQVIA’s stock was adversely impacted by policy changes affecting the industry with the stock price going from a high of $209.96 to its low at mid-year of $137.00.” · word for word
High leverage
“Ended 2025 with a Net Leverage Ratio of 3.63x” · word for word
Restructuring risk
“Completed a rigorous assessment of organizational structure and talent deployment to improve operational effectiveness, resulting in the elimination of approximately 3,300 roles” · word for word
17 Feb 202610-KEmployees 93,000; Unique non-identified patient records 1,200,000,000; Proprietary data size 68open
Figures in the filing · each found in the filing text
| Employees · 2025-12-31 | 93,000 | |
| Unique non-identified patient records · Technology & Analytics Solutions · 2025-12-31 | 1,200,000,000 | |
| Proprietary data size · Technology & Analytics Solutions · 2025-12-31 | 68 | |
| Data suppliers · Technology & Analytics Solutions · 2025-12-31 | 150,000 | |
| Healthcare records received annually · Technology & Analytics Solutions · FY2025 | 120,000,000,000 | |
| Clients · 2025-12-31 | 10,000 |
Risks flagged
Contract termination risk
“Most of our Research & Development Solutions clients can terminate our contracts upon 30 to 90 days' notice.” · word for word
Data dependency risk
“Our Commercial Solutions information services are derived from data we collect from third parties. ... suppliers may increase restrictions on our use of such data, increase the price they charge us for data or refuse altogether to license the data to us.” · word for word
Cybersecurity risk
“Security breaches and unauthorized use of our IT systems and information, or the IT systems or information in the possession of our vendors, could expose us, our clients, our data suppliers or others to risk of loss.” · word for word
5 Feb 20268-K · 2.02Revenue $4.36B (+10% y/y); Revenue $16.31B (+6% y/y); GAAP Net Income $514M (+18% y/y); Guidance: FY26 revenue guidance $17.15B-$17.35B vs FY25 $16.31B; Adjusted EBITDA $3.975B-$4.025B vs FY25 $3.788Bearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q4-2025 | $4.36B | +10% y/y |
| Revenue · FY2025 | $16.31B | +6% y/y |
| GAAP Net Income · Q4-2025 | $514M | +18% y/y |
| GAAP Net Income · FY2025 | $1.36B | -1% y/y |
| Adjusted EBITDA · Q4-2025 | $1.05B | +5% y/y |
| Adjusted EBITDA · FY2025 | $3.79B | +3% y/y |
| GAAP Diluted EPS · Q4-2025 | $2.99 | +24% y/y |
| Adjusted Diluted EPS · Q4-2025 | $3.42 | +10% y/y |
| R&D Solutions contracted backlog · R&D Solutions · Q4-2025 | $32.70B | +5% y/y |
| R&D Solutions revenue · R&D Solutions · Q4-2025 | $2.33B | +10% y/y |
Guidance
FY26 revenue guidance $17.15B-$17.35B vs FY25 $16.31B; Adjusted EBITDA $3.975B-$4.025B vs FY25 $3.788B
Strong Q4 beat; FY26 guidance implies continued growth; backlog strength supports outlook.
Risks flagged
High leverage; net debt $13.7B; net leverage 3.63x. Interest expense expected to increase ~$80M in FY26.
“Net debt of $13,744 million; Net Leverage Ratio was 3.63x. Guidance includes step up in interest expense of approximately $80 million.”
28 Oct 20258-K · 2.02Revenue $4.10B (+5% y/y); GAAP Net Income $331M; Adjusted EBITDA $949M (+1% y/y); Guidance: FY2025 revenue $16,150M-$16,250M; Adjusted EBITDA $3,775M-$3,800M; Adjusted EPS $11.85-$11.95earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $4.10B | +5% y/y |
| GAAP Net Income · Q3-2025 | $331M | |
| Adjusted EBITDA · Q3-2025 | $949M | +1% y/y |
| GAAP Diluted EPS · Q3-2025 | $1.93 | |
| Adjusted Diluted EPS · Q3-2025 | $3.00 | |
| R&D Solutions quarterly bookings · R&D Solutions · Q3-2025 | $2.60B | +13% y/y |
| R&D Solutions contracted backlog · R&D Solutions · Q3-2025 | $32.40B | +4% y/y |
| Operating Cash Flow · Q3-2025 | $908M | |
| Free Cash Flow · Q3-2025 | $772M | +35% y/y |
| TAS revenue · Technology & Analytics Solutions · Q3-2025 | $1.63B | +5% y/y |
Guidance
FY2025 revenue $16,150M-$16,250M; Adjusted EBITDA $3,775M-$3,800M; Adjusted EPS $11.85-$11.95
Reaffirmed midpoint of FY2025 guidance and narrowed ranges; strong demand indicators including RFP growth of 20% YoY.
Risks flagged
Net leverage ratio 3.52x trailing twelve-month Adjusted EBITDA; debt $14,957M.
“Net Leverage Ratio was 3.52x trailing twelve-month Adjusted EBITDA; debt was $14,957 million.” · word for word
COVID-related revenue step-down of ~$100M in FY2025 guidance.
“Revenue guidance includes approximately $100 million of COVID-related revenue step-down, entirely in R&DS.” · word for word
28 Oct 202510-QIQVIA reported Q3 2025 revenue growth of 5.2% YoY, with mixed margin performance and increased backlog.earningsopen
Figures in the filing · each found in the filing text
| Total revenues · Q3-2025 | $4.10B | +5% y/y |
| Backlog · Research & Development Solutions · Q3-2025 | $32.40B | |
| Employees · Q3-2025 | 91,000 | |
| Technology & Analytics Solutions revenue · Technology & Analytics Solutions · Q3-2025 | $1.63B | +5% y/y |
| Research & Development Solutions revenue · Research & Development Solutions · Q3-2025 | $2.26B | +5% y/y |
| Contract Sales & Medical Solutions revenue · Contract Sales & Medical Solutions · Q3-2025 | $209M | +16% y/y |
| Operating cash flow · 9M-2025 | $1.92B | +5% y/y |
Risks flagged
Cost inflation pressure
“Cost of revenues as a percentage of revenues increased from 64.6% to 66.5% in Q3 2025 vs Q3 2024, driven by compensation and related expenses.”
Restructuring execution risk
“Restructuring costs of $81 million for the first nine months of 2025, with actions expected to continue into 2026.”
IQVIA Holdings Inc. — questions
- What did IQVIA Holdings Inc. file recently?
- 18 SEC filings in the last 12 months. Latest: 8-K on 2026-09-23 — IQVIA Inc. issued $2B of 6.375% senior notes due 2034 to refinance existing debt and repay revolver borrowings.
Every figure on this page comes from IQVIA Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.